Insight | Peptides like BPC-157: promising science, thin evidence, real risks
Several discussions of peptide therapeutics cover compounds like BPC-157, TB-500 and growth-hormone-releasing peptides. They describe exciting early data on healing and metabolism alongside limited human trials and sourcing risks. Readers tempted by peptide hype need that balance before experimenting.
Peptides such as BPC-157, TB-500 and the growth-hormone-releasing peptides are exciting, but the excitement runs well ahead of the human evidence. They should be seen as potent, early-stage drugs, not harmless supplements.
Dr. Craig Koniver, a physician who has prescribed peptides for about eight years, makes the clinical case. BPC-157 has been his most-used peptide, and he reports thousands of patients who became less stiff and sore, with better knees and shoulders. He says injections under the skin worked better than oral forms and that he saw no notable side effects. He describes the growth hormone peptides as tools with different flavors, such as ipamorelin, the cleanest but weakest, and he caps most of them at 100 micrograms. His approach is to stay within what the body would see in nature. His confidence rests on clinical observation, not published trials, which both men say openly.
Andrew Huberman makes the case for caution. Almost all the data come from rats and mice. He knows of only one human study on BPC-157, which he calls poorly performed, so placebo effects cannot be ruled out. His most serious warning concerns how the peptide heals: it grows new blood vessels, and tumors thrive on blood flow and growth factors. In his words, "BPC 157 is a potential tumor growth risk," and anyone with a known cancer or concerns about tumors should be very cautious. He adds that growth hormone peptides can raise prolactin and cortisol, and that his own trial of sermorelin wiped out his late-night REM sleep and raised his prostate specific antigen.
They agree on the guardrails: clean pharmacy sourcing, conservative doses, cycling off and monitoring. Sourcing is a safety issue in its own right. Products sold for research purposes only can be contaminated, and Koniver has seen anaphylactic reactions to them.
They differ on details. Koniver's clinic used up to 5,000 micrograms of BPC-157 a day, five days on and two off; Huberman describes 300 to 500 micrograms two or three times a week for about eight weeks, then a long break. Koniver likes stacking BPC-157 with growth hormone peptides, while Huberman sees that combination as a possible way to feed a tumor. A tumor risk would not show up as a side effect patients notice.
The rules are shifting too. In October 2023 the FDA barred compounding pharmacies from making BPC-157 and many other peptides, and some have since been allowed again.
What to do with it: try the free levers first. Protect deep early-night sleep, stop eating about two hours before bed and train hard, which Huberman says can raise growth hormone several-fold. If you pursue peptides, never use research-only products, use the minimum effective dose, cycle off and track your own response. Screen for tumors before using growth-promoting peptides. On seeing a doctor, Huberman is direct: "I implore you to do so with a board certified physician".





